October 8, 2021 the U.S. Food and Drug Administration (FDA) approved avacopan (trade name: Taveneos), an oral complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis).
Dr. John Cush RheumNow
4 years 11 months ago
The CDC estimates of the national prevalence of arthritis and arthritis-attributable activity limitations (AAAL) show a continued increase in absolute number: 58.5 million US adults have arthritis, 25.7 million of whom have AAAL.
Read more on #RheumNow
https://t.co/9RNIduVCZh https://t.co/fzxWMbcEfU
Dr. John Cush RheumNow
4 years 11 months ago
Most common reasons for starting canakinumab? Survey of 58 MDs (caring for 147 febrile pts) 1) perceived efficacy(81%), 2) lack of prior response (41%), 3) good safety (40%). Efficacy w/ HIDS/MKD (91%), no response w/ FMF (52%) https://t.co/JjxaUyBnyB
Dr. John Cush RheumNow
4 years 11 months ago
Clinical Associations with Myositis Antibodies
Read the full article on #RheumNow
https://t.co/tzPU1scc8x https://t.co/xxF1gIulwY
Dr. John Cush RheumNow
4 years 11 months ago
ICYMI: Several studies have suggested that biologic Rx of Psoriasis may lower risk of later PsA. New study of nearly 2 million PSO (15k given biologic, 20K given oral Rx). The risk developing PsA higher w/ biologic (aHR 4.48) vs oral or phototherapy https://t.co/Na5EfWelkY https://t.co/0sL18UWjhO
Dr. John Cush RheumNow
4 years 11 months ago
We are reviewing cases from Ask Cush Anything and almost a dozen news items and reports on this week’s podcast. Download today.
https://t.co/Xb81eWEZ1q https://t.co/K6zPKtwAD7
Dr. John Cush RheumNow
4 years 11 months ago
ICYMI: An erosive hand osteoarthritis (EOA) study from the Osteoarthritis Initiative shows that EOA is more common in older women and is strongly linked to further progressive, articular structural damage.
https://t.co/XOVKNj423l
#RheumNow https://t.co/CYxW6mJpCH
Dr. John Cush RheumNow
4 years 11 months ago
ICYMI:
Upadacitinib RA program (5306 pts) the risk of H. zoster by Rx and dose (HZ/100PYs)
MTX = 0.8/100PY
ADA+MTX= 1.1/100PY
UPA 15 mg= 3.0/100PY
UPA 30 mg = 5.3/100PY
Hence there is a 4-5X risk of HZ w/ JAKinhibitors
https://t.co/wo9ih5PJ77
#RheumNow https://t.co/h1GoGzADdv
Dr. John Cush RheumNow
4 years 11 months ago
ICYMI:
“Hiker’s feet” newly proposed cutaneous foot manifestations of dermatomyositis. Most pts had the antisynthetase syndrome (with anti-Jo-1) and almost all had mechanic’s hands. Such findings should prompt a search for ILD https://t.co/98EAQUHJbz https://t.co/Cw6rSIUyW2
Dr. John Cush RheumNow
4 years 11 months ago
ICYMI:
The AAOS has published their Clinical Practice Guideline for Management of Osteoarthritis of the Knee (Non-Arthroplasty); updating 19 of 29 evidence-based recommendations and focuses on nonsurgical treatmentss to provide pain and patient function.
https://t.co/faLi0WQt8F https://t.co/PI7jYN1VB9
Dr. John Cush RheumNow
4 years 11 months ago
ICYMI:
Secukinumab (IL-17 inhibitors) can be safely used in HIV spondyloarthritis patients. https://t.co/hpCRJkR9w7 https://t.co/qwbrvGkriX
Dr. John Cush RheumNow
4 years 11 months ago
ICYMI:
ASBMR meeting presented results of the ASTEROID trial in osteogenesis imperfecta; Setrusumab, investigational Mab inhibitor of sclerostin, failed to improve radial trabecular BMD (primary endpt), but did improve lumbar/hip/femoral BMD https://t.co/xSDIiffjb7 https://t.co/H4Cl8rH3Bq
Dr. John Cush RheumNow
4 years 11 months ago
ACR 2021 is just a few weeks away - are you ready? I'll review cases and questions submitted by viewers in Ask Cush Anything (#ACA). This, and nearly a dozen news items and reports, are discussed in this week's podcast.
https://t.co/Xb81eWEZ1q https://t.co/bJqkEyx2Mg
Dr. John Cush RheumNow
4 years 11 months ago
Read more about Pathways to a Psoriatic Arthritis diagnosis on #RheumNow
https://t.co/lIaddvq4q1 https://t.co/G6BOUMvyjc
Dr. John Cush RheumNow
4 years 11 months ago
An erosive hand osteoarthritis (EOA) study from the Osteoarthritis Initiative shows that EOA is more common in older women and is strongly linked to further progressive, articular structural damage.
https://t.co/XOVKNj423l https://t.co/gaPfj17IrB
